- Conditions
- Liver Cirrhosis
- Interventions
- Placebo, Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet, Rifaximin SSD 80 mg SER tablet, Rifaximin SSD 80mgIR/80mgSER tablet
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 420 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 113
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 125
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Hypertrophic Cardiomyopathy
- Interventions
- Valsartan, Placebo
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 8 Years to 45 Years
- Enrollment
- 211 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 13
- States / cities
- Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
- Conditions
- Major Depressive Disorder, Recurrent, Unspecified
- Interventions
- LY03005, Placebo
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Marlton, New Jersey
- Conditions
- Myalgia, Hypercholesterolemia, Hyperlipidemia
- Interventions
- PPD10558, Atorvastatin, Placebo
- Drug
- Lead sponsor
- Furiex Pharmaceuticals, Inc
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 282 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 67
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Huntington Park, California + 60 more
- Conditions
- Gout, Moderate Renal Impairment
- Interventions
- Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 189 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 89
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more
- Conditions
- Schnitzler Syndrome, Urticarial Vasculitis With Monoclonal Immunoglobulin M Component, Schnitzler (Disorder)
- Interventions
- 80 mg RPH-104, Placebo
- Biological · Drug
- Lead sponsor
- R-Pharm Overseas, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Denver, Colorado • Rochester, Minnesota • Portland, Oregon + 1 more
- Conditions
- Obesity
- Interventions
- Placebo (Cohorts 1 and 2), PF-06882961 (Cohorts 1 and 2), Placebo (Cohort 3), PF-06882961 (Cohort 3)
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 628 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 27
- States / cities
- Anniston, Alabama • Anaheim, California • Los Angeles, California + 23 more
- Conditions
- Coccidioidomycosis
- Interventions
- Placebo, VT-1598
- Other · Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Schizophrenia
- Interventions
- LY2140023, Placebo
- Drug
- Lead sponsor
- Denovo Biopharma LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 8
- States / cities
- Oakland, California • San Diego, California • Torrance, California + 5 more
- Conditions
- Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
- Interventions
- Ziprasidone, Placebo
- Drug
- Lead sponsor
- VA Palo Alto Health Care System
- Federal
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Tampa, Florida • Mason, Ohio
- Conditions
- Depression, Major Depressive Disorder
- Interventions
- Levomilnacipran ER, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 734 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 30
- States / cities
- Beverly Hills, California • Encino, California • Garden Grove, California + 26 more
- Conditions
- Influenza
- Interventions
- 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo
- Drug
- Lead sponsor
- Biota Scientific Management Pty Ltd
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 639 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 70
- States / cities
- Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more
- Conditions
- Joint Damage
- Interventions
- Febuxostat, Placebo for Febuxostat
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 56
- States / cities
- Mesa, Arizona • Tucson, Arizona • Burbank, California + 53 more
- Conditions
- ECG Effects
- Interventions
- Buprenorphine transdermal patch, Naltrexone tablet, Placebos (for TDS and for naltrexone and for moxifloxacin), Moxifloxacin tablet
- Drug
- Lead sponsor
- Purdue Pharma LP
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- Atomoxetine Hydrochloride, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 502 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 20
- States / cities
- Irvine, California • Gainesville, Florida • Tampa, Florida + 17 more
- Conditions
- COVID-19, SARS-CoV-2
- Interventions
- AZD5156 (Parent study Sentinel Safety Cohort), Placebo (Parent study Sentinel Safety Cohort), EVUSHELD™ (Parent study Main Cohort), AZD3152 (Parent study Main Cohort), Placebo (Parent study Main Cohort), AZD3152 (Sub-study), AZD7442 - EVUSHELD™ (Sub-study), AZD7442 (EVUSHELD™) (Sub-study) Immunocompromised participants offered AZD3152
- Biological
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 12 Years to 130 Years
- Enrollment
- 3,882 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 130
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Glendale, Arizona + 108 more
- Conditions
- Vascular Aging
- Interventions
- Placebo, Sodium Nitrite
- Drug
- Lead sponsor
- University of Colorado, Boulder
- Other
- Eligibility
- 50 Years to 79 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Boulder, Colorado
- Conditions
- Bipolar Disorder
- Interventions
- Ziprasidone oral capsules, placebo oral capsules
- Drug
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 238 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Orange, California • San Diego, California + 41 more
- Conditions
- Crohn's Disease
- Interventions
- Adalimumab, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 514 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Dothan, Alabama • La Jolla, California + 41 more
- Conditions
- Hypochondriasis
- Interventions
- Fluoxetine, Cognitive Behavioral Therapy (CBT), Supportive Therapy, Placebo
- Drug · Behavioral · Other
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Crohn's Disease
- Interventions
- adalimumab, placebo
- Biological
- Lead sponsor
- Abbott
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 135 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 7
- States / cities
- Atlanta, Georgia • Chicago, Illinois • Chevy Chase, Maryland + 4 more
- Conditions
- Immune Thrombocytopenic Purpura
- Interventions
- Dexamethasone USP Micronized, Prednisone
- Drug
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 15 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 18
- States / cities
- New Orleans, Louisiana • Baltimore, Maryland • Boston, Massachusetts + 10 more
- Conditions
- Attention Deficit Hyperactivity Disorder
- Interventions
- HLD200 methylphenidate hydrochloride (MPH) Capsules, Placebo
- Drug
- Lead sponsor
- Ironshore Pharmaceuticals and Development, Inc
- Other
- Eligibility
- 6 Years to 12 Years
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 7
- States / cities
- Newport Beach, California • Bradenton, Florida • Maitland, Florida + 4 more
- Conditions
- Hypertension
- Interventions
- Azilsartan Medoxomil Low-dose, Losartan, Placebo for Azilsartan Medoxomil, Placebo for Losartan, Azilsartan Medoxomil Medium-dose (20 mg), Azilsartan Medoxomil High-dose (40 mg)
- Drug
- Lead sponsor
- Arbor Pharmaceuticals, Inc.
- Industry
- Eligibility
- 6 Years to 18 Years
- Enrollment
- 377 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 17
- States / cities
- Anaheim, California • Hialeah, Florida • Miami, Florida + 12 more